Sustained reductions in migraine frequency over more than four years were found with use of erenumab (Aimovig, Amgen and Novartis), according to pre-publication results of a five-year, open-label trial in patients with episodic migraines.
The study results were presented at the American Headache Society’s 61st Annual Scientific Meeting, in Philadelphia (abstract IOR10).